{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:25:09Z","timestamp":1768681509798,"version":"3.49.0"},"reference-count":45,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI119187"],"award-info":[{"award-number":["AI119187"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM008804"],"award-info":[{"award-number":["GM008804"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Influenza viruses are respiratory pathogens that are responsible for annual influenza epidemics and sporadic influenza pandemics. Oseltamivir (Tamiflu\u00ae) is currently the only FDA-approved oral drug that is available for the prevention and treatment of influenza virus infection. However, its narrow therapeutic window, coupled with the increasing incidence of drug resistance, calls for the next generation of influenza antivirals. In this study, we discovered hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral through forward chemical genomics screening. Hesperadin inhibits multiple human clinical isolates of influenza A and B viruses with single to submicromolar efficacy, including oseltamivir-resistant strains. Mechanistic studies revealed that hesperadin inhibits the early stage of viral replication by delaying the nuclear entry of viral ribonucleoprotein complex, thereby inhibiting viral RNA transcription and translation as well as viral protein synthesis. Moreover, a combination of hesperadin with oseltamivir shows synergistic antiviral activity, therefore hesperadin can be used either alone to treat infections by oseltamivir-resistant influenza viruses or used in combination with oseltamivir to delay resistance evolution among oseltamivir-sensitive strains. In summary, the discovery of hesperadin as a broad-spectrum influenza antiviral offers an alternative to combat future influenza epidemics and pandemics.<\/jats:p>","DOI":"10.3390\/ijms18091929","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T02:01:30Z","timestamp":1505095290000},"page":"1929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral"],"prefix":"10.3390","volume":"18","author":[{"given":"Yanmei","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiantao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Musharrafieh","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Hau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlong","family":"Ma","sequence":"additional","affiliation":[{"name":"BIO5 Institute, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA"},{"name":"BIO5 Institute, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Webster, R.G., Monto, A.S., Braciale, T.J., and Lamb, R.A. (2013). Textbook of Influenza, Wiley.","DOI":"10.1002\/9781118636817"},{"key":"ref_2","unstructured":"Knipe, D.M., and Howley, P.M. (2007). Orthomyxoviridae: The Viruses and Their Replication. Fields Virology, Lippincott Williams & Wilkins. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","unstructured":"(2017, July 15). People at High Risk of Developing Flu\u2013Related Complications, Available online: https:\/\/www.cdc.gov\/flu\/about\/disease\/high_risk.htm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(16)00153-5","article-title":"Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997\u20132015: A systematic review of individual case data","volume":"16","author":"Lai","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.coviro.2016.01.020","article-title":"Emergence and development of H7N9 influenza viruses in China","volume":"16","author":"Zhu","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bip.22623","article-title":"Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses","volume":"104","author":"Wang","year":"2015","journal-title":"Biopolymers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: Towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., and He, H. (2015). Adamantane-resistant influenza a viruses in the world (1902\u20132013): Frequency and distribution of M2 gene mutations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119115"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/jiq005","article-title":"Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008\u20132010","volume":"203","author":"Sheu","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.7326\/0003-4819-156-7-201204030-00411","article-title":"Antivirals for treatment of influenza: A systematic review and meta-analysis of observational studies","volume":"156","author":"Hsu","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/rmv.703","article-title":"The host interactome of influenza virus presents new potential targets for antiviral drugs","volume":"21","author":"Shaw","year":"2011","journal-title":"Rev. Med. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2009.12.017","article-title":"The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus","volume":"139","author":"Brass","year":"2009","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature07151","article-title":"Drosophila RNAi screen identifies host genes important for influenza virus replication","volume":"454","author":"Hao","year":"2008","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature08760","article-title":"Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication","volume":"463","author":"Karlas","year":"2010","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nature08699","article-title":"Human host factors required for influenza virus replication","volume":"463","author":"Konig","year":"2010","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cell.2009.12.018","article-title":"A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection","volume":"139","author":"Shapira","year":"2009","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.virol.2009.02.046","article-title":"The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza","volume":"387","author":"Sui","year":"2009","journal-title":"Virology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chom.2014.11.002","article-title":"Influenza virus-host interactome screen as a platform for antiviral drug development","volume":"16","author":"Watanabe","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.200208092","article-title":"The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint","volume":"161","author":"Hauf","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/mol.116.105346","article-title":"Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers","volume":"90","author":"Ma","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1128\/AAC.01417-09","article-title":"Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing","volume":"54","author":"Deyde","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1128\/JCM.43.8.4139-4146.2005","article-title":"Enhanced Expression of an \u03b12,6-Linked Sialic Acid on MDCK Cells Improves Isolation of Human Influenza Viruses and Evaluation of Their Sensitivity to a Neuraminidase Inhibitor","volume":"43","author":"Hatakeyama","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2017.01.006","article-title":"An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses","volume":"140","author":"Hu","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2016.07.019","article-title":"Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance","volume":"133","author":"Ma","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2174\/1568026617666170224122508","article-title":"Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein As A Hot Antiviral Drug Target","volume":"17","author":"Hu","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2013.07.018","article-title":"New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions","volume":"100","author":"Beyleveld","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_31","first-page":"241","article-title":"Comparison of methods for evaluating drug-drug interaction","volume":"2","author":"Zhao","year":"2010","journal-title":"Front. Biosci. Elite Ed."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","article-title":"Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection","volume":"96","author":"Lee","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.chom.2015.11.002","article-title":"Meta- and Orthogonal Integration of Influenza \u201cOMICs\u201d Data Defines a Role for UBR4 in Virus Budding","volume":"18","author":"Tripathi","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014The major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2013.05.007","article-title":"Cytosolic sensing of viruses","volume":"38","author":"Goubau","year":"2013","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1039\/C4MD00045E","article-title":"Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery","volume":"5","author":"Patel","year":"2014","journal-title":"Med. Chem. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2015.00278","article-title":"Aurora Kinase Inhibitors: Current Status and Outlook","volume":"5","author":"Bavetsias","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acs.jmedchem.5b01910","article-title":"Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel","volume":"59","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.26.4.476","article-title":"Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses","volume":"26","author":"Huggins","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Odds, F.C. (2003). Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother., 52.","DOI":"10.1093\/jac\/dkg301"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/9\/1929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:44:24Z","timestamp":1760208264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/9\/1929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["ijms18091929"],"URL":"https:\/\/doi.org\/10.3390\/ijms18091929","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}